243 related articles for article (PubMed ID: 37823214)
1. Progress, implications, and challenges in using humanized immune system mice in CAR-T therapy-Application evaluation and improvement.
Yue H; Bai L
Animal Model Exp Med; 2024 Feb; 7(1):3-11. PubMed ID: 37823214
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology modeling of chimeric antigen receptor T therapies.
Kumari R; Ouyang X; Wang J; Xu X; Zheng M; An X; Li QX
Curr Opin Pharmacol; 2021 Dec; 61():49-61. PubMed ID: 34619442
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
5. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models.
Si X; Xiao L; Brown CE; Wang D
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328572
[TBL] [Abstract][Full Text] [Related]
9. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model.
Teng R; Zhao J; Zhao Y; Gao J; Li H; Zhou S; Wang Y; Sun Q; Lin Z; Yang W; Yin M; Wen J; Deng H
J Immunother; 2019; 42(2):33-42. PubMed ID: 30586347
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of response and resistance to CAR T cell therapies.
Berger TR; Maus MV
Curr Opin Immunol; 2021 Apr; 69():56-64. PubMed ID: 33752101
[TBL] [Abstract][Full Text] [Related]
14. Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells.
Vincent RL; Li F; Ballister ER; Arpaia N; Danino T
J Vis Exp; 2024 Feb; (204):. PubMed ID: 38372353
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
16. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
17. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
18. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
Front Immunol; 2021; 12():782775. PubMed ID: 34790207
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
